Alan Lobo

8.3k total citations
142 papers, 4.8k citations indexed

About

Alan Lobo is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Alan Lobo has authored 142 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Genetics, 61 papers in Epidemiology and 56 papers in Surgery. Recurrent topics in Alan Lobo's work include Inflammatory Bowel Disease (69 papers), Microscopic Colitis (49 papers) and Diverticular Disease and Complications (21 papers). Alan Lobo is often cited by papers focused on Inflammatory Bowel Disease (69 papers), Microscopic Colitis (49 papers) and Diverticular Disease and Complications (21 papers). Alan Lobo collaborates with scholars based in United Kingdom, United States and France. Alan Lobo's co-authors include David S. Sanders, David P. Hurlstone, Marios Hadjivassiliou, Simon S. Cross, Mark McAlindon, G.A.B. Davies-Jones, A. A. M. Gibson, Steven R. Brown, Timothy J. Stephenson and A. J. Shorthouse and has published in prestigious journals such as The Lancet, Gastroenterology and PLoS ONE.

In The Last Decade

Alan Lobo

130 papers receiving 4.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan Lobo United Kingdom 39 2.1k 2.0k 1.9k 1.8k 790 142 4.8k
Sung-Ae Jung South Korea 36 1.1k 0.5× 1.4k 0.7× 697 0.4× 714 0.4× 1.0k 1.3× 228 4.0k
Donald A. Antonioli United States 41 1.4k 0.7× 4.3k 2.1× 1.4k 0.8× 1.3k 0.7× 640 0.8× 101 6.5k
Pierre Paré Canada 28 1.2k 0.5× 1.8k 0.9× 1.8k 1.0× 1.3k 0.7× 241 0.3× 63 4.0k
Pieter Stokkers Netherlands 45 2.5k 1.2× 2.2k 1.1× 574 0.3× 4.0k 2.2× 1.0k 1.3× 133 6.4k
Thomas Ochsenkühn Germany 37 1.9k 0.9× 1.6k 0.8× 448 0.2× 2.8k 1.5× 644 0.8× 99 5.0k
Karel Geboes Belgium 24 1.7k 0.8× 1.7k 0.9× 501 0.3× 2.2k 1.2× 345 0.4× 94 4.1k
K Gecse Netherlands 34 2.2k 1.0× 1.9k 1.0× 596 0.3× 3.1k 1.7× 468 0.6× 174 4.6k
Scott A. Strong United States 33 1.8k 0.8× 2.4k 1.2× 261 0.1× 2.7k 1.5× 1.4k 1.7× 87 5.6k
Ragnar Befrits Sweden 29 1000 0.5× 837 0.4× 371 0.2× 1.1k 0.6× 301 0.4× 86 2.7k
Pieter Hindryckx Belgium 28 1.5k 0.7× 1.1k 0.6× 349 0.2× 2.1k 1.1× 442 0.6× 88 3.5k

Countries citing papers authored by Alan Lobo

Since Specialization
Citations

This map shows the geographic impact of Alan Lobo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Lobo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Lobo more than expected).

Fields of papers citing papers by Alan Lobo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Lobo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Lobo. The network helps show where Alan Lobo may publish in the future.

Co-authorship network of co-authors of Alan Lobo

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Lobo. A scholar is included among the top collaborators of Alan Lobo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Lobo. Alan Lobo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hauer, J.F., et al.. (2025). T Cells Enhance Tissue Complexity and Function to Study Fibrosis in 3D Skin-Like Tissue Models. Tissue Engineering Part C Methods. 31(7). 248–260.
2.
Hall, Jamie, Daniel Hind, Stephen J. Walters, et al.. (2025). Mesenteric excision and Kono‐S anastomosis trial (MEErKAT): A study protocol for a multicentre, 2 × 2 factorial, randomised controlled, open‐label superiority trial. Colorectal Disease. 27(9). e70212–e70212. 1 indexed citations
3.
Morgan, Jenna, et al.. (2025). The challenges of implementing earlier surgery for terminal ileal Crohn's disease—A qualitative study of the clinician's perspective. Colorectal Disease. 27(2). e70027–e70027. 1 indexed citations
4.
Wyld, Lynda, Alan Lobo, Jenna Morgan, et al.. (2025). The patient and clinician perspective on ‘early’ bowel resection for terminal ileal Crohn's disease (EBRIC): protocol for a multicentre mixed‐methods study. Colorectal Disease. 27(3). e70042–e70042. 1 indexed citations
5.
Hind, Daniel, et al.. (2024). Inequalities in Healthcare Access, Experience and Outcomes in Adults With Inflammatory Bowel Disease: A Scoping Review. Inflammatory Bowel Diseases. 30(12). 2486–2499. 6 indexed citations
6.
7.
Raju, Suneil A, Imran Aziz, Mo Thoufeeq, et al.. (2024). What is the role of out of programme clinical fellowships in the era of Shape of Training? A single-centre cohort study. BMJ Open Gastroenterology. 11(1). e001311–e001311.
8.
Steyerberg, Ewout W., María José Casanova, Guillaume Bouguen, et al.. (2023). Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies. Journal of Crohn s and Colitis. 18(1). 134–143. 2 indexed citations
9.
10.
Coates, Elizabeth, Nyantara Wickramasekera, Amy Barr, et al.. (2022). Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study. Health Technology Assessment. 26(41). 1–118. 3 indexed citations
11.
Barr, Amy, Elizabeth Coates, Nyantara Wickramasekera, et al.. (2021). P96 Factors influencing treatment preferences in steroid resistant ulcerative colitis – a qualitative interview study. A90.2–A91. 1 indexed citations
12.
13.
Baker, Daniel, et al.. (2020). A systematic review and meta‐analysis of outcomes after elective surgery for ulcerative colitis. Colorectal Disease. 23(1). 18–33. 34 indexed citations
14.
15.
Robinson, Kerry H., et al.. (2014). PTU-094 Do We Need Post Infliximab Infusion Monitoring?. Gut. 63(Suppl 1). A80.2–A81.
16.
Wright, A, Kerry H. Robinson, Reena Sidhu, et al.. (2014). PTU-083 Use Of Polymerase Chain Reaction To Detect Mucosal Cytomegalovirus Infection In Patients With Acute Ulcerative Colitis. Gut. 63(Suppl 1). A75.2–A76. 1 indexed citations
17.
18.
Leeds, John, Andrew D. Hopper, David P. Hurlstone, et al.. (2007). Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms?. Alimentary Pharmacology & Therapeutics. 25(3). 265–271. 71 indexed citations
19.
Lobo, Alan, Roger J. Leicester, John Gibson, et al.. (1998). Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology. 114(1). 15–22. 139 indexed citations
20.
Crabtree, J. E., et al.. (1990). Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.. Gut. 31(9). 1033–1036. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sung-Ae Jung Breakdown of academic impact, for papers by Donald A. Antonioli Breakdown of academic impact, for papers by Pierre Paré Breakdown of academic impact, for papers by Pieter Stokkers Breakdown of academic impact, for papers by Thomas Ochsenkühn Breakdown of academic impact, for papers by Karel Geboes Breakdown of academic impact, for papers by K Gecse Breakdown of academic impact, for papers by Scott A. Strong Breakdown of academic impact, for papers by Ragnar Befrits Breakdown of academic impact, for papers by Pieter Hindryckx
Rankless by CCL
2026